Hjem
Einar Svarstads bilde

Einar Svarstad

Professor II
  • E-postEinar.Svarstad@uib.no
  • Telefon+47 55 97 29 79
  • Besøksadresse
    Haukeland Universitetssykehus Laboratoriebygget, 7. etg. Heis øst
  • Postadresse
    Postboks 7804
    5020 Bergen
Vitenskapelig artikkel
  • Vis forfatter(e) 2021. Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus. Molecular Genetics and Metabolism. 234-243.
  • Vis forfatter(e) 2020. The changing landscape of Fabry disease. Journal of the American Society of Nephrology. 569-576.
  • Vis forfatter(e) 2020. Early indicators of disease progression in Fabry disease that may indicate the need for disease-specific treatment initiation: Findings from the opinion-based PREDICT-FD modified Delphi consensus initiative. BMJ Open. 1-12.
  • Vis forfatter(e) 2020. Accumulation of Globotriaosylceramide in Podocytes in Fabry Nephropathy Is Associated with Progressive Podocyte Loss. Journal of the American Society of Nephrology. 865-875.
  • Vis forfatter(e) 2019. Developing nephrology services in low income countries: A case of Tanzania. BMC Nephrology. 1-9.
  • Vis forfatter(e) 2018. Low birth weight associates with glomerular area in young male IgA nephropathy patients. BMC Nephrology. 1-10.
  • Vis forfatter(e) 2018. In vivo detection of chronic kidney disease using tissue deformation fields from dynamic MR imaging. IEEE Transactions on Biomedical Engineering. 1779-1790.
  • Vis forfatter(e) 2017. Pathomechanisms of renal Fabry disease. Cell and Tissue Research. 53-62.
  • Vis forfatter(e) 2017. Outcome in biopsy-proven Lupus nephritis: Evaluation of biopsies from the Norwegian Kidney Biopsy Registry. Lupus. 881-885.
  • Vis forfatter(e) 2017. Long-term dose-dependent agalsidase effects on kidney histology in fabry disease. American Society of Nephrology. Clinical Journal. 1470-1479.
  • Vis forfatter(e) 2017. Iohexol plasma clearance in children: validation of multiple formulas and single-point sampling times. Pediatric nephrology (Berlin, West). 1-14.
  • Vis forfatter(e) 2017. Bedside stereomicroscopy of Fabry kidney biopsies: An easily available method for diagnosis and assessment of sphingolipid deposits. Nephron. 13-21.
  • Vis forfatter(e) 2016. The variation in high sensitive cardiac troponin concentration during haemodialysis treatment is not similar to the biological variation observed in stable end stage renal disease patients. Scandinavian Journal of Clinical and Laboratory Investigation. 645-652.
  • Vis forfatter(e) 2016. Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients. Nephrology, Dialysis and Transplantation. 807-813.
  • Vis forfatter(e) 2016. Quantifcation of single-kidney function and volume in living kidney donors using dynamic contrast-enhanced MRI. American Journal of Roentgenology. 1022-1030.
  • Vis forfatter(e) 2016. Polyvinylpyrrolidone induced artefactual prolongation of activated partial thromboplastin times in intravenous drug users with renal failure. Journal of Thrombosis and Haemostasis. 936-939.
  • Vis forfatter(e) 2016. One Year of Enzyme Replacement Therapy Reduces Globotriaosylceramide Inclusions in Podocytes in Male Adult Patients with Fabry Disease. PLOS ONE.
  • Vis forfatter(e) 2016. Low birth weight and risk of progression to end stage renal disease in IgA nephropathy - A retrospective registry-based cohort study. PLOS ONE.
  • Vis forfatter(e) 2016. Iohexol plasma clearance in children: validation of multiple formulas and two-point sampling times. Pediatric nephrology (Berlin, West). 311-320.
  • Vis forfatter(e) 2016. Familial Factors, Low Birth Weight, and Development of ESRD: A Nationwide Registry Study. American Journal of Kidney Diseases. 601-608.
  • Vis forfatter(e) 2016. End stage renal disease predicts increased risk of death in first degree relatives in the Norwegian population. PLOS ONE.
  • Vis forfatter(e) 2016. Dynamic contrast-enhanced MRI measurement of renal function in healthy participants. Acta Radiologica. 748-757.
  • Vis forfatter(e) 2015. Use of 3D DCE-MRI for the estimation of renal perfusion and glomerular filtration rate: An intrasubject comparison of FLASH and KWIC with a comprehensive framework for evaluation. American Journal of Roentgenology. W273-W281.
  • Vis forfatter(e) 2015. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: The European Fabry Working Group consensus document. Orphanet Journal of Rare Diseases. 1-10.
  • Vis forfatter(e) 2015. Global collaboration bears fruit: Tanzania report. Kidney International. 1211-1214.
  • Vis forfatter(e) 2015. Foot process effacement is an early marker of nephropathy in young classic fabry patients without albuminuria. Nephron. 16-21.
  • Vis forfatter(e) 2015. Chronic kidney disease and an uncertain diagnosis of Fabry disease: approach to a correct diagnosis. Molecular Genetics and Metabolism. 242-247.
  • Vis forfatter(e) 2015. Addition of eGFR and age improves the prognostic absolute renal risk-model in 1,134 norwegian patients with IgA nephropathy. American Journal of Nephrology. 210-219.
  • Vis forfatter(e) 2014. Weekly and 90-minute biological variations in cardiac troponin T and cardiac troponin I in hemodialysis patients and healthy controls. Clinical Chemistry. 838-847.
  • Vis forfatter(e) 2014. Uncertain diagnosis of fabry disease in patients with neuropathic pain, angiokeratoma or cornea verticillata: consensus on the approach to diagnosis and follow-up. JIMD Reports. 83-90.
  • Vis forfatter(e) 2014. Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry disease. PLOS ONE.
  • Vis forfatter(e) 2014. Familial clustering of ESRD in the Norwegian population. American Society of Nephrology. Clinical Journal. 1692-1700.
  • Vis forfatter(e) 2014. CD11c+ dendritic cells rather than Langerhans cells are reduced in normal skin of immunosuppressed renal transplant recipients. Acta Dermato-Venereologica. 173-178.
  • Vis forfatter(e) 2013. Preeclampsia in healthy women and endothelial dysfunction 10 years later. American Journal of Obstetrics and Gynecology. 569.e1-569.e10.
  • Vis forfatter(e) 2013. Preeclampsia and prevalence of microalbuminuria 10 years later. American Society of Nephrology. Clinical Journal. 1126-1134.
  • Vis forfatter(e) 2013. Mortality in patients with IgA nephropathy. American Journal of Kidney Diseases. 883-890.
  • Vis forfatter(e) 2013. Agalsidase Benefits Renal Histology in Young Patients with Fabry Disease. Journal of the American Society of Nephrology. 137-148.
  • Vis forfatter(e) 2012. Safety and complications of percutaneous kidney biopsies in 715 children and 8573 adults in Norway 1988-2010. American Society of Nephrology. Clinical Journal. 1591-1597.
  • Vis forfatter(e) 2012. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrology, Dialysis and Transplantation. 1042-1049.
  • Vis forfatter(e) 2012. Recommendations on Reintroduction of Agalsidase Beta for Patients with Fabry Disease in Europe, Following a Period of Shortage. JIMD Reports.
  • Vis forfatter(e) 2011. Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. Kidney International. 663-670.
  • Vis forfatter(e) 2011. Laboratory investigation and follow-up of chronic kidney disease stage 3 in primary care. Clinica Chimica Acta. 1138-1142.
  • Vis forfatter(e) 2010. Scoring system for renal pathology in Fabry disease: Report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrology, Dialysis and Transplantation. 2168-2177.
  • Vis forfatter(e) 2010. Phenotypic Variation in a Large Family with Autosomal Dominant Hypocalcaemia. Hypertension in Pregnancy. 399-405.
  • Vis forfatter(e) 2010. Monitoring renal function in children with Fabry disease: comparisons of measured and creatinine-based estimated glomerular filtration rate. Nephrology, Dialysis and Transplantation. 1507-1513.
  • Vis forfatter(e) 2010. Modelling the resource implications of managing adults with Fabry disease in Norway favours home infusion. European Journal of Clinical Investigation. 1104-1112.
  • Vis forfatter(e) 2009. The MDRD equation may mask decline of glomerular filtration rate in Fabry patients with normal or nearly normal kidney function. Clinical Nephrology. 118-124.
  • Vis forfatter(e) 2009. Nephrogenic systemic fibrosis and use of MR contrast media. Tidsskrift for Den norske legeforening. 180-182.
  • Vis forfatter(e) 2009. Monitoring renal Function in Fabry children: comparisons of measured and creatinine-based estimated Glomerular Filtration Rate. Nephrology, Dialysis and Transplantation. 7 sider.
  • Vis forfatter(e) 2008. Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. American Journal of Kidney Diseases. 767-776.
  • Vis forfatter(e) 2008. En kvinne med kronisk nyresvikt, progredierende hudforkalkninger og sepsis. Tidsskrift for Den norske legeforening.
  • Vis forfatter(e) 2007. Long-term risk of cancer in membranous nephropathy patients. American Journal of Kidney Diseases. 396-403.
  • Vis forfatter(e) 2005. Focal and segmental glomerular sclerosis (FSGS) in a man and a woman with Fabry's disease. Clinical Nephrology. 394-401.
  • Vis forfatter(e) 2005. Critical renal artery stenoses may cause a spectrum of cardiorenal failure and associated thromboembolic events. Clinical Nephrology. 487-492.
  • Vis forfatter(e) 2004. Bedside stereomicroscopy of renal biopsies may lead to a rapid diagnosis of Fabry's disease. Nephrology, Dialysis and Transplantation. 3202-3203.
  • Vis forfatter(e) 2003. C2 monitoring in maintenance renal transplant recipients: is it worthwhile? Transplantation. 1236-1238.
  • Vis forfatter(e) 2002. Effect of light excercise on renal hemodynamics in patients with hypertension and chronic renal disease. Scandinavian Journal of Urology and Nephrology. 464-473.
  • Vis forfatter(e) 2001. Sympathetic nervous system overactivity in hypertensive patients with chronic renal failure. Role of upright body position. Scandinavian Journal of Urology and Nephrology. 393-400.
  • Vis forfatter(e) 2001. Renal hemodynamic effects of captopril and doxazosin during slight physical activity in hypertensive patients with type-1 diabetes mellitus. Kidney and Blood Pressure Research. 64-70.
  • Vis forfatter(e) 2001. Akutt nyresvikt, nyrearteriestenose og angiotensinkonvertase (ACE)-hemmer. Tidsskrift for Den norske legeforening. 1784-1788.
  • Vis forfatter(e) 2001. Akutt dialysebehandling ved Haukeland Sykehus i 1999. Tidsskrift for Den norske legeforening. 1774-1779.
Vitenskapelig foredrag
  • Vis forfatter(e) 2021. Cleared Podocytes and Normal Kidney Function in Classical Fabry Males 15 Years After Start of Enzyme Replacement Therapy at Young Age.
  • Vis forfatter(e) 2020. Polyvinylpyrrolidon (PVP) lagringssykdom hos ruspasienter – en case-serie.
  • Vis forfatter(e) 2019. Renal Polyvinylpyrrolidone Deposition from Illicit Drug Use is Associated with Tubulointerstitial Nephropathy.
  • Vis forfatter(e) 2019. Fabry Nephropathy: First mRNA-seq Findings from Kidney Biopsies Before and After Enzyme Replacement Therapy.
  • Vis forfatter(e) 2013. Podocytes: Therapeutic Target in Fabry Disease?
  • Vis forfatter(e) 2010. 5 YEARS FOLLOW-UP RENAL BIOPSIES IN PAEDIATRIC AND ADULT FABRY PATIENTS ON ENZYME REPLACEMENT THERAPY.
  • Vis forfatter(e) 2009. Corneal changes in Fabry's disease.
  • Vis forfatter(e) 2001. Ultralyd og Doppler av nyrer.
  • Vis forfatter(e) 2001. Akutt nyresvikt, epidemiologi og nyreerstattende behandling.
  • Vis forfatter(e) 2001. Akutt nyresvikt (forekomst, diagnostikk, dialyseindikasjon).
  • Vis forfatter(e) 2001. ACE-hemmere og nyresvikt.
Leder
  • Vis forfatter(e) 2011. A Mother and Daughter with Unexplained Renal Failure. Nephron. C1-C9.
Leserinnlegg
  • Vis forfatter(e) 2013. Week-to-Week Biological Variation in the N-terminal Prohormone of Brain Natriuretic Peptide in Hemodialysis Patients and Healthy Individuals. Clinical Chemistry. 1813-1814.
  • Vis forfatter(e) 2012. En mann i 50-årene med feber, hoste og anuri. Tidsskrift for Den norske legeforening. 1621-1624.
  • Vis forfatter(e) 2012. En kvinne i 50-årene med smerter i beina og nyresvikt. Tidsskrift for Den norske legeforening. 960-961.
  • Vis forfatter(e) 2011. Fabry or not Fabry – a question of ascertainment. European Journal of Human Genetics. 1111-1112.
  • Vis forfatter(e) 2002. Renal artery thrombosis with acute renal failure after withdrawal of angiotensin converting enzyme inhibitor: a case report. Nephrology, Dialysis and Transplantation. 687-689.
Brev til redaktøren
  • Vis forfatter(e) 2015. Renal failure due to excessive intake of almonds in the absence of Oxalobacter Formigenes. American Journal of Medicine. e29-e30.
  • Vis forfatter(e) 2015. Renal Failure due to Excessive Intake of Almonds in the Absence of Oxalobacter formigenes. American Journal of Medicine.
  • Vis forfatter(e) 2004. Renal artery thrombosis and acute renal failure after ACE inhibition. Nephrology, Dialysis and Transplantation. 565.
Doktorgradsavhandling
  • Vis forfatter(e) 2001. Renal hemodynamics in ambulatory patients with chronic renal disease. -.
Intervju
  • Vis forfatter(e) 2013. Enzyme replacement in Fabry disease.
Vitenskapelig Kapittel/Artikkel/Konferanseartikkel
  • Vis forfatter(e) 2009. Ultralydveiledet biopsi og annen intervensjon. 4 sider.
  • Vis forfatter(e) 2009. Ultralyd av nyrer og urinveier. 12 sider.
Sammendrag/abstract
  • Vis forfatter(e) 2013. Renal structural-functional relationship (SFR) studies suggest that podocyte GL-3 accumulation predicts urine protein creatinine ratio in Fabry disease (FD) nephropathy (FDN). Molecular Genetics and Metabolism. S68-S69.
  • Vis forfatter(e) 2012. VALIDATION OF FRENCH MODEL TO PREDICT ESRD AND DEATH IN IGA NEPHROPATHY PATIENTS. Nephrology, Dialysis and Transplantation. 189-190.
  • Vis forfatter(e) 2012. STANDARDIZED MORTALITY RATE IN IGA NEPHROPATHY PATIENTS. Nephrology, Dialysis and Transplantation. 188-188.
  • Vis forfatter(e) 2012. OUTCOME IN BIOPSY-PROVEN LUPUS NEPHRITIS. Nephrology, Dialysis and Transplantation. 182-182.
  • Vis forfatter(e) 2012. Mosaicism of Podocyte Involvement in Untreated Females with Fabry Disease. Molecular Genetics and Metabolism. S47-S48.
  • Vis forfatter(e) 2010. The Potential Importance of Renal Biopsies in Early Management Decisions in Young Fabry Patients. Clinical Therapeutics. S97-S98.
  • Vis forfatter(e) 2010. SCORING SYSTEM FOR RENAL PATHOLOGY IN FABRY DISEASE: REPORT OF THE INTERNATIONAL STUDY GROUP OF FABRY NEPHROPATHY (ISGFN). Clinical Therapeutics. S105-S105.
  • Vis forfatter(e) 2010. RENAL FOLLOW-UP BIOPSIES IN YOUNG MALE FABRY PATIENTS ON ENZYME REPLACEMENT THERAPY. Clinical Therapeutics. S105-S107.
  • Vis forfatter(e) 2010. Natural history and structural-functional relationships (SFR) in Fabry nephropathy (FN). Molecular Genetics and Metabolism. S27-S28.
  • Vis forfatter(e) 2009. Monitoring renal Function in Fabry children; estimated or measured glomerular Filtration rate? Molecular Genetics and Metabolism. 74-75.
  • Vis forfatter(e) 2009. Fabry Disease: Unusual Symptoms in two Boys Treated with Lamotrigine and Fabrazyme, Respectively. Clinical Therapeutics. S43-S43.
  • Vis forfatter(e) 2008. Prominence of glomerular and vascular changes in renal biopsies in children and adolescents with Fabry disease and microalbuminuria. Clinical Therapeutics. S42-S42.
Poster
  • Vis forfatter(e) 2019. Clinical Consequences of Paired Cardiac and Kidney Biopsies in a Treatment Naive Female Fabry Patient with a Classical Mutation and Minor Clnical Symptoms.
  • Vis forfatter(e) 2019. Accumulation of Globotriaosylceramide in Podocytes (PC) in Fabry Nephropathy Is Associated with Progressive PC Loss.
  • Vis forfatter(e) 2018. SINGLE INTRAVENOUS ACCESS FOR MEASUREMENT OF GLOMERULAR FILTRATION RATE IN CHILDREN AFTER MARKER INJECTION.
  • Vis forfatter(e) 2018. Podocyte structural parameters predict glomerular filtration rate (GFR) loss in male patients with classic Fabry disease.
  • Vis forfatter(e) 2018. IOHEXOL CLEARANCE IN CHILDREN WITH LOW GFR: COMPARISON OF 24 HOURS SINGLE-POINT GFR AND MULTIPLE-POINT GFR.
  • Vis forfatter(e) 2018. Fabry nephropathy: Transcriptome sequencing of microdissected renal compartments from archival kidney biopsies at baseline, and after 5 & 10 years of enzyme replacement therapy.
  • Vis forfatter(e) 2017. Single-point iohexol plasma clearance in children: validation of multiple formulas and sampling times.
  • Vis forfatter(e) 2017. Simplified Clinical Pre-histologic Scoring Method of Kidney Biopsies in Fabry Disease.
  • Vis forfatter(e) 2017. Podocyte globotriaosylceramide (GL-3) content strongly impacts age-dependent podocyte loss in ERT-naïve male Fabry patients.
  • Vis forfatter(e) 2016. Podocyte Hypertrophy and Globotriaosylceramide (GL-3) Accumulation Are Strong Predictors of Podocyte Loss in Enzyme Replacement Therapy Naïve Male Patients with Fabry Disease.
  • Vis forfatter(e) 2016. Differential response of glomerular parietal epithelial cells and podocytes to enzyme replacement therapy in Fabry nephropathy.
  • Vis forfatter(e) 2015. Podocyte Globotriaosylceramide (GL3) Accumulation in Fabry Disease Is Influenced by Age and Genotype .
  • Vis forfatter(e) 2015. LONG-TERM ENZYME REPLACEMENT THERAPY (ERT) BENEFITS THE GLOMERULI MORE THAN THE VASCULATURE IN YOUNGER FABRY NEPHROPATHY .
  • Vis forfatter(e) 2015. FABRY DISEASE DIAGNOSED IN LIVING DONOR KIDNEY TRANSPLANT BIOPSY.
  • Vis forfatter(e) 2015. DIFFERENTIAL KIDNEY EFFECTS OF HIGH AND LOW ENZYME DOSE IN MALE SIBLINGS TREATED FOR 13 YEARS .
  • Vis forfatter(e) 2014. Renal Biopsies after 6-11 Years of Enzyme Replacement Therapy in 9 Young Classic Fabry Disease Patients.
  • Vis forfatter(e) 2014. Quantification of glomerular filtration rate (GFR) using a modelbased MR renography technique provides good agreement with IohexolGFR and eGFR in 20 healthy subjects. .
  • Vis forfatter(e) 2014. Five Children with Fabry Disease and Significant Tissue Damage in Renal Biopsies Despite Normal Clinical Renal Parameters.
  • Vis forfatter(e) 2014. Fabry nephropathy (FN) outcome and the impact of diagnostic kidney biopsies after 10 years enzyme replacement therapy (ERT).
  • Vis forfatter(e) 2014. Enzyme Replacement Therapy (ERT) in Fabry Disease (FD) Reduces Podocyte (PC) Globotriaosylceramide (GL3) Content within a Year (yr).
  • Vis forfatter(e) 2014. Consensus recommendation on Fabry disease diagnosis in adult patients with kidney disease.
  • Vis forfatter(e) 2013. Glomerular filtration rate (GFR) measured by iohexolclearance in children; how many sample points are necessary?
  • Vis forfatter(e) 2009. Renal follow-up biopsies in young male Fabry patients on enzyme replacement therapy.
  • Vis forfatter(e) 2008. Renal biopsies in children in Norway 1988-2005: clinical variables, complications and prognosis.
  • Vis forfatter(e) 2008. Formula GFR overestimates Renal Function in Children and Adult Males with Fabry Disease and Stage 1-2 CKD.
  • Vis forfatter(e) 2005. Glomerular and vascular changes are prominent in renal biopsies in children and adolescents with Fabry disease and microalbuminuria.
  • Vis forfatter(e) 2004. Early signs of focal and segmental glomerulosclerosis (FSGS) and arteriolopathy is prevalent in Fabry patients with minimal proteinuria or slightly reduced GFR.
  • Vis forfatter(e) 2001. Vitamin D, tartrate-resistent acid phosphatase 5B and osteocalcin in bone metabolism in patients undergoing hemodialysis (HD).
  • Vis forfatter(e) 2001. Vitamin D Resistant Acid Phosphatase 5B and Osteocalcin in Bone Metabolism in Patients (PTS) Undergoing Hemodialysis (HD).
  • Vis forfatter(e) 2001. Substatntial loss of 1.25 (OH)2 D3 in the urine in patients with nephrotic syndrome.
  • Vis forfatter(e) 2001. A simplified therapy regimen with epoetin alfa is sufficient in most HD-patients.
Errata
  • Vis forfatter(e) 2016. Erratum to: Iohexol plasma clearance in children: validation of multiple formulas and two-point sampling times (Pediatric Nephrology, (2017), 32, 2, (311-320), 10.1007/s00467-016-3436-z). Pediatric nephrology (Berlin, West). 375-376.
Vitenskapelig oversiktsartikkel/review
  • Vis forfatter(e) 2020. Proteomics for the study of new biomarkers in Fabry disease: State of the art. Molecular Genetics and Metabolism. 86-93.
  • Vis forfatter(e) 2013. Renal complications of Fabry disease in children. Pediatric nephrology (Berlin, West). 679-687.
  • Vis forfatter(e) 2012. Assessment of Kidney Volumes From MRI: Acquisition and Segmentation Techniques. American Journal of Roentgenology. 1060-1069.
  • Vis forfatter(e) 2009. Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations. Nephrology, Dialysis and Transplantation. 1736-1743.
  • Vis forfatter(e) 2009. Nefrogen systemisk fibrose ved bruk av MR-kontrastmiddel. Tidsskrift for Den norske legeforening. 180-182.
  • Vis forfatter(e) 2009. Kognitiv svikt ved terminal nyresykdom. Tidsskrift for Den norske legeforening. 296-299.

Se fullstendig oversikt over publikasjoner i CRIStin.

Forskergrupper